drugset / Trial / NCT04005755
Maxigesic® IV Phase 3 Exposure Study
NaSingle-groupOpen-labelTreatment
Summary
The study aims to determine the tolerability of repeated doses of Maxigesic® IV over an extended period of exposure.
Timeline
- Start
- 2019-07-22
- Primary completion
- 2020-06-30
- Completion
- 2020-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acetaminophen | Small molecule | 1000 mg | Intravenous |
| Subject | Ibuprofen | Small molecule | 300 mg | Intravenous |
Indications
No indication recorded.